Study S000139

Addition of a Glucagon-like Peptide-1 to a Calorie Restricted Diet Augments Weight Loss and Decreases Risk of Type 2 Diabetes and Cardiovascular Disease.

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT01784965
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: TRIPLE
Status: COMPLETED
Enrollment: 69
Start: 2009-12
Primary completion: 2012-12
Lead sponsor: Stanford University
Conditions: Pre-diabetes; Older Adults
Interventions: DRUG:liraglutide; DRUG:Placebo
Results posted: TRUE
Individual participant data sharing: NO

Registered primary outcomes

Change in Weight Reported at 14 Weeks [Baseline and 14 weeks]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0026677	Pancreatic beta cell function following liraglutide-augmented weight loss in individuals with prediabetes: analysis of a randomised, placebo-controlled study. Kim SH, Diabetologia	2014	Randomized trial	PMID 24326527 DOI	cites ClinicalTrials.gov:NCT01784965; registry reference DERIVED:24326527
R0026736	Benefits of liraglutide treatment in overweight and obese older individuals with prediabetes. Kim SH, Diabetes care	2013	Randomized trial	PMID 23835684 DOI	cites ClinicalTrials.gov:NCT01784965; registry reference DERIVED:23835684